ReviewCancers2022
Electrochemotherapy: An Alternative Strategy for Improving Therapy in Drug-Resistant SOLID Tumors.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Imaging and Histopathological Findings of Phyllodes Tumor of the Prostate in a Cat.Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association · 2026Article
- Electrical resistance measurement in feline cutaneous squamous cell carcinoma treated with electrochemotherapy: a pilot study.Scientific reports · 2026Article
- Minimization of Cancellation Effect with Nisin During Bipolar Nanosecond Electrochemotherapy.International journal of molecular sciences · 2026Article
- Silent forces, hidden currents: the influence of static magnetic field stimulation on tumor biophysics.npj biomedical innovations · 2026Review
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Tumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination.Biomedicines · 2025Review
- The Role of Electrochemotherapy in Managing Cutaneous Metastases from Breast Carcinoma: A Narrative Review.Biomedicines · 2025Review
- Article
- Modulating the Cell Death Immune Response for Electroporation Treatments.Bioelectricity · 2024Article
- Application of Gold Nanoparticles for Improvement of Electroporation-Assisted Drug Delivery and Bleomycin Electrochemotherapy.Pharmaceutics · 2024Article
- Phytocompounds and Nanoformulations for Anticancer Therapy: A Review.Molecules (Basel, Switzerland) · 2024Review
- Electrochemotherapy for head and neck cancers: possibilities and limitations.Frontiers in oncology · 2024Review
- Safety and Feasibility of Analgosedation for Electrochemotherapy of Liver Lesions.Life (Basel, Switzerland) · 2023Article
- Evaluating the role of polysaccharide extracted from Pleurotus columbinus on cisplatin-induced oxidative renal injury.Scientific reports · 2023Article
- Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination.Cancers · 2022Review
- Electrochemotherapy for Recurrence and/or Metastatic Skin Cancers: A Prospective Case Series in Iran.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrochemotherapy (ECT) is one of the innovative strategies to overcome the multi drug resistance (MDR) that often occurs in cancer. Resistance to anticancer drugs results from a variety of factors, such as genetic or epigenetic changes, an up-regulated outflow of drugs, and various cellular and molecular mechanisms. This technology combines the administration of chemotherapy with the application of electrical pulses, with waveforms capable of increasing drug uptake in a non-toxic and well tolerated mechanical system. ECT is used as a first-line adjuvant therapy in veterinary oncology, where it improves the efficacy of many chemotherapeutic agents by increasing their uptake into cancer cells. The chemotherapeutic agents that have been enhanced by this technique are bleomycin, cisplatin, mitomycin C, and 5-fluorouracil. After their use, a better localized control of the neoplasm has been observed. In humans, the use of ECT was initially limited to local palliative therapy for cutaneous metastases of melanoma, but phase I/II studies are currently ongoing for several histotypes of cancer, with promising results. In this review, we described the preclinical and clinical use of ECT on drug-resistant solid tumors, such as head and neck squamous cell carcinoma, breast cancer, gynecological cancer and, finally, colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.